Advertisement
UK markets closed
  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     
  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     
  • AIM

    789.87
    +6.17 (+0.79%)
     
  • GBP/EUR

    1.1629
    +0.0018 (+0.15%)
     
  • GBP/USD

    1.2533
    +0.0009 (+0.07%)
     
  • Bitcoin GBP

    48,257.30
    -1,261.27 (-2.55%)
     
  • CMC Crypto 200

    1,256.16
    -101.85 (-7.50%)
     
  • S&P 500

    5,215.33
    +1.25 (+0.02%)
     
  • DOW

    39,478.50
    +90.74 (+0.23%)
     
  • CRUDE OIL

    78.31
    -0.95 (-1.20%)
     
  • GOLD FUTURES

    2,375.20
    +34.90 (+1.49%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     
  • DAX

    18,772.85
    +86.25 (+0.46%)
     
  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     

GW cannabis-derived epilepsy drug gets positive FDA staff review

GW cannabis-derived epilepsy drug gets positive FDA staff review

GW Pharmaceuticals' cannabis-derived medicine for severe childhood epilepsy won a favorable review from U.S. Food and Drug Administration (FDA) staff on Tuesday, boosting hopes for its approval in the world's biggest drugs market. GW's medicine Epidiolex, which is given as a syrup, is a purified form of cannabidiol, one of the active ingredients found in marijuana. It is designed to treat Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), rare childhood-onset forms of epilepsy that are among the most resistant to treatment.